3.22.4 html 70 204 1 false 32 0 false 6 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Consolidated Balance Sheets Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 100040 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 100050 - Statement - Consolidated Statements of Cash Flows Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 100060 - Disclosure - Nature of the Business and Summary of Significant Accounting Policies Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPolicies Nature of the Business and Summary of Significant Accounting Policies Notes 7 false false R8.htm 100070 - Disclosure - Net Loss Per Common Share Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShare Net Loss Per Common Share Notes 8 false false R9.htm 100080 - Disclosure - Fair Value of Financial Instruments Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments Fair Value of Financial Instruments Notes 9 false false R10.htm 100090 - Disclosure - Accounts Payable, Accrued Expenses and Other Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureAccountsPayableAccruedExpensesAndOther Accounts Payable, Accrued Expenses and Other Notes 10 false false R11.htm 100110 - Disclosure - Common Stock Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureCommonStock Common Stock Notes 11 false false R12.htm 100120 - Disclosure - Stock-Based Compensation Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation Stock-Based Compensation Notes 12 false false R13.htm 100130 - Disclosure - Income Taxes Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes Income Taxes Notes 13 false false R14.htm 100140 - Disclosure - Subsequent Events Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureSubsequentEvents Subsequent Events Notes 14 false false R15.htm 100150 - Disclosure - Nature of the Business and Summary of Significant Accounting Policies (Policies) Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesPolicies Nature of the Business and Summary of Significant Accounting Policies (Policies) Policies http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPolicies 15 false false R16.htm 100160 - Disclosure - Net Loss Per Common Share (Tables) Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareTables Net Loss Per Common Share (Tables) Tables http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShare 16 false false R17.htm 100170 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstruments 17 false false R18.htm 100180 - Disclosure - Accounts Payable, Accrued Expenses and Other (Tables) Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureAccountsPayableAccruedExpensesAndOtherTables Accounts Payable, Accrued Expenses and Other (Tables) Tables http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureAccountsPayableAccruedExpensesAndOther 18 false false R19.htm 100200 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensation 19 false false R20.htm 100210 - Disclosure - Income Taxes (Tables) Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxes 20 false false R21.htm 100220 - Disclosure - Nature of the Business and Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureNatureOfBusinessAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Nature of the Business and Summary of Significant Accounting Policies - Additional Information (Detail) Details 21 false false R22.htm 100230 - Disclosure - Net Loss Per Common Share - Schedule of Securities Excluded from Computation of Diluted Loss Per Share (Detail) Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureNetLossPerCommonShareScheduleOfSecuritiesExcludedFromComputationOfDilutedLossPerShareDetail Net Loss Per Common Share - Schedule of Securities Excluded from Computation of Diluted Loss Per Share (Detail) Details 22 false false R23.htm 100240 - Disclosure - Fair Value of Financial Instruments - Summary of Assets Measured at Fair Value on a Recurring Basis (Detail) Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsSummaryOfAssetsMeasuredAtFairValueOnRecurringBasisDetail Fair Value of Financial Instruments - Summary of Assets Measured at Fair Value on a Recurring Basis (Detail) Details 23 false false R24.htm 100250 - Disclosure - Fair Value of Financial Instruments - Additional Information (Detail) Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureFairValueOfFinancialInstrumentsAdditionalInformationDetail Fair Value of Financial Instruments - Additional Information (Detail) Details 24 false false R25.htm 100260 - Disclosure - Accounts Payable, Accrued Expenses and Other - Schedule of Accounts Payable, Accrued Expenses and Other (Detail) Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureAccountsPayableAccruedExpensesAndOtherScheduleOfAccountsPayableAccruedExpensesAndOtherDetail Accounts Payable, Accrued Expenses and Other - Schedule of Accounts Payable, Accrued Expenses and Other (Detail) Details 25 false false R26.htm 100290 - Disclosure - Common Stock - Additional Information (Detail) Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureCommonStockAdditionalInformationDetail Common Stock - Additional Information (Detail) Details 26 false false R27.htm 100300 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetail Stock-Based Compensation - Additional Information (Detail) Details 27 false false R28.htm 100310 - Disclosure - Stock-Based Compensation - Schedule of Assumptions Used to Calculate Fair Value of Options Granted to Employees (Detail) Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsUsedToCalculateFairValueOfOptionsGrantedToEmployeesDetail Stock-Based Compensation - Schedule of Assumptions Used to Calculate Fair Value of Options Granted to Employees (Detail) Details 28 false false R29.htm 100320 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail) Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail Stock-Based Compensation - Summary of Stock Option Activity (Detail) Details 29 false false R30.htm 100330 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 30 false false R31.htm 100340 - Disclosure - Income Taxes - Schedule of Reconciliation of the Company's Effective Tax Rate to the Statutory Federal Income Tax Rate (Detail) Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfCompanySEffectiveTaxRateToStatutoryFederalIncomeTaxRateDetail Income Taxes - Schedule of Reconciliation of the Company's Effective Tax Rate to the Statutory Federal Income Tax Rate (Detail) Details 31 false false R32.htm 100350 - Disclosure - Income Taxes - Schedule of Temporary Differences That Give Rise to Significant Net Deferred Tax Assets (Detail) Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfTemporaryDifferencesThatGiveRiseToSignificantNetDeferredTaxAssetsDetail Income Taxes - Schedule of Temporary Differences That Give Rise to Significant Net Deferred Tax Assets (Detail) Details 32 false false R33.htm 100360 - Disclosure - Income Taxes - Schedule of Changes in the Valuation Allowance (Detail) Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfChangesInValuationAllowanceDetail Income Taxes - Schedule of Changes in the Valuation Allowance (Detail) Details 33 false false R34.htm 100370 - Disclosure - Subsequent Events - Additional Information (Detail) Sheet http://www.merrimackpharma.com/20221231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetail Subsequent Events - Additional Information (Detail) Details 34 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 3 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, dei:EntityRegistrantName, mack:MaximumMaturityPeriodForInvestmentsToBeClassifiedAsCashAndCashEquivalentsDescription - mack-20221231.htm 8 mack-20221231.htm mack-20221231.xsd mack-20221231_cal.xml mack-20221231_def.xml mack-20221231_lab.xml mack-20221231_pre.xml mack-ex21_1.htm mack-ex23_1.htm mack-ex31_1.htm mack-ex31_2.htm mack-ex32_1.htm mack-ex32_2.htm mack-ex4_5.htm mack-ex4_51.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true